Artelo biosciences, inc. (ARTL)

CashFlow / TTM
Feb'20Nov'19Aug'19May'19Feb'19Nov'18Aug'18May'18Feb'18Nov'17Aug'17May'17Feb'17Nov'16Aug'16May'16Feb'16Nov'15Aug'15May'15Feb'15Nov'14
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net Income (Loss) Attributable to Parent

-3,866,971

-2,921,634

-2,172,176

-2,016,688

-2,249,662

-2,623,337

-2,343,491

-1,769,107

-1,287,882

-502,429

-234,889

-123,491

-31,909

-23,988

-29,690

-29,950

-27,400

-28,460

-15,241

0

0

0

Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Share-based Payment Arrangement, Noncash Expense

615,171

552,078

425,110

497,348

217,358

313,804

290,004

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

618

564

510

416

276

280

282

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Represents the change in fair value for the period of warrant derivative liability.

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (Decrease) in Operating Capital [Abstract]
Prepaid expenses

81,317

41,287

-27,048

-29,911

3,666

30,061

35,384

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other receivable

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivable

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase (Decrease) in Accounts Payable and Accrued Liabilities

-149,088

-55,169

-180,409

131,115

261,681

500,726

500,696

418,314

321,908

123,922

15,636

62,705

-4,996

7,351

11,201

0

0

0

-

-

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-58,862

-26,043

-4,231

-18,489

-21,341

-21,491

-27,260

-13,502

0

0

0

Net Cash Provided by (Used in) Operating Activities

-4,104,664

-3,443,173

-2,792,676

-2,245,452

-2,114,767

-1,841,283

-1,610,020

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchase of equipment

-

-

-

-

-

-

845

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Provided by (Used in) Investing Activities

-

-

-

-

-

-

-845

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from issuance of common stock

-

-

8,376,379

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issuance costs

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Represents amount of refund for fractional stock.

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collection from stock subscription

-

-

-

-

-

-

-

-

-

0

-

-

-

0

600

0

0

0

-

-

-

-

Due to related party

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

-

-

Advance from related party

16,621

18,924

18,276

13,644

11,386

13,629

19,894

39,783

41,068

34,536

24,585

3,274

3,950

3,850

4,450

0

0

0

-

-

-

-

Proceeds from (Repayments of) Related Party Debt

-15,047

-19,710

-17,228

-9,541

-7,434

-10,109

-18,056

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

283,110

33,350

3,850

5,050

0

0

0

-

-

-

-

Net Cash Provided by (Used in) Financing Activities

7,104,780

8,189,551

8,377,427

2,205,567

2,056,333

1,550,907

1,388,451

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations

26,967

13,919

2,478

947

-9,387

-7,012

-12,937

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-235,351

97,528

513,553

408,193

568,528

224,248

7,307

-381

-13,439

-8,991

-4,491

-10,260

2,298

0

0

0

Supplemental Cash Flow Information [Abstract]
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

Interest Paid, Excluding Capitalized Interest, Operating Activities

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Income Taxes Paid, Net

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

0

-

-

-

-

Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Amount of common shares issued for acquisition of license offset against stock payable.

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amount of common shares issued for settlement of stock payable.

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Loan forgiven by previous shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Share subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0